Date: 2013-01-16
Type of information: Production agreement
Compound: NYESO-1c259-T cell therapy product
Company: Adaptimmune (UK) NeoStem (USA) Progenitor Cell Therapy (USA)
Therapeutic area: Cancer - Oncology
Type agreement: manufacturing
production
services
Action mechanism:
Disease:
Details: NeoStem, its subsidiary, Progenitor Cell Therapy, and Adaptimmune have announced a services agreement under which Progenitor Cell Therapy will provide services to support Adaptimmune’s NYESO-1c259-T cell therapy product being developed for multiple oncology indications. Three clinial trials are currently ongoing for multiple myeloma, synovial sarcoma and metastatic melanoma).
PCT’s services will include the transfer and qualification of Adaptimmune’s manufacturing process for its NYESO-1c259-T cell therapy product candidate at PCT’s facility in Allendale, New Jersey and subsequent manufacturing of the product for Adaptimmune’s clinical trials.
Financial terms:
Latest news:
